Author: Howard

[Job Opening] Business Development Manager – San Diego office

Yuhan USA Corporation was established in January 2018 as a wholly-owned subsidiary of Yuhan Corporation, Korea’s largest pharmaceutical company with a 94-year heritage. As an outpost of Yuhan’s globalization strategy, Yuhan USA is seeking new opportunities to expand its business domain through searching new drug materials and companies that match with Yuhan’s targeted therapeutic areas […]

Yuhan-AbClon now in the race for a COVID-19 therapeutic antibody

Yuhan and AbClon have joined the list of pharmaceutical companies that are in the race to develop a therapeutic antibody for COVID-19. They have identified a multifariously adaptive candidate for COVID-19 therapy, which they plan to begin testing on humans before the end of this year. According to Yuhan and Abclon, their antibody in a […]

Yuhan expands its allergy treatment pipeline with the in-license of GI-301 from GI Innovation

Yuhan Corporation has in-licensed GI Innovation’s allergy treatment pipeline (GI-301) from GI Innovation in a deal that could potentially total $1.2 billion. Yuhan and GI Innovation’s collaboration to develop next-generation allergy treatment will cover all four major allergic diseases, which are allergic asthma, chronic urticaria, atopic dermatitis, and food allergy. Under this license and co-development […]

Yuhan Corporation to recoup KRW 200 billion investment in five years

Yuhan Corporation’s global R&D and open innovation strategy – in which they introduce early assets from the startups, conduct preclinical & early clinical studies, then license them out to the pharmaceutical giants – is now reaping its benefits. Yuhan, which formerly led the Korean pharmaceutical industry with its sales force, has transformed itself into an […]

J&J’s Experimental Lung Cancer Drug Receives Breakthrough Therapy Designation

Here’s an update from our business partner Janssen Biotech that JNJ-6372 in combination with Lazertinib (YH25448), a novel third-generation EGFR TKI for advanced NSCLC that Yuhan Corporation out-licensed to them in November 2018, received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA). – Article from Johnson & Johnsonhttps://lnkd.in/gFMri6P – Article from BioSpacehttps://lnkd.in/gjNTGqh